Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dipika Singh

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Nature Communications|February 3, 2025
A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer typesZhen Zeng, Tianbei Zhang, Jiajia Zhang, et al.
Gynecologic Oncology|August 21, 2025
A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancerStéphanie Gaillard, Jade Alvarez, Tianbei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.
Nature Medicine|November 9, 2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trialPatrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.
The Journal of Clinical Investigation|April 8, 2021
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronavirusesArbor G Dykema, Boyang Zhang, Bezawit A Woldemeskel, et al.
Nature Medicine|March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Science Immunology|September 15, 2023
Lung tumor-infiltrating T<sub>reg</sub> have divergent transcriptional profiles and function linked to checkpoint blockade responseArbor G Dykema, Jiajia Zhang, Laurene S Cheung, et al.
Nature|July 22, 2021
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X Caushi, Jiajia Zhang, Zhicheng Ji, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Nature Communications|February 3, 2025
A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer typesZhen Zeng, Tianbei Zhang, Jiajia Zhang, et al.
Gynecologic Oncology|August 21, 2025
A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancerStéphanie Gaillard, Jade Alvarez, Tianbei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.
Nature Medicine|November 9, 2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trialPatrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.
The Journal of Clinical Investigation|April 8, 2021
Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronavirusesArbor G Dykema, Boyang Zhang, Bezawit A Woldemeskel, et al.
Nature Medicine|March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Science Immunology|September 15, 2023
Lung tumor-infiltrating T<sub>reg</sub> have divergent transcriptional profiles and function linked to checkpoint blockade responseArbor G Dykema, Jiajia Zhang, Laurene S Cheung, et al.
Nature|July 22, 2021
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X Caushi, Jiajia Zhang, Zhicheng Ji, et al.
Pageof 2